Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Metabolic Diseases Pipeline Analysis:Focus on Dyslipidemia, Diabetes, and Obesity

Published by: Decision Resources

Published: Nov. 5, 2005 - 83 Pages

The price of this report has been reduced due to its age. The original price was $9,500 for PDF.

Table of Contents


Executive Summary

Which companies are the major players in the metabolic disease market?

Which companies are the emerging players developing promising treatments for metabolic diseases?

What is the commercial outlook for the metabolic disease market?

Chapter 1. Background of a Worldwide Epidemic

Chapter 2. Overview of Metabolic Diseases

Type 2 Diabetes

Obesity

Dyslipidemia

Metabolic Syndrome

Non-Alcoholic Steatohepatitis

Polycystic Ovarian Syndrome

Chapter 3. Current and Emerging Treatments for Metabolic
Diseases

Drugs Targeting Type 2 Diabetes

Insulin

Inhaled Insulin

Oral Insulin

Sulfonylurea Drugs

Meglitinides

Biguanides

Alpha-Glucosidase Inhibitors

PPAR Agonists (Thiazolidinediones)

Amylin Analogues

Incretin Mimetics

DPP-IV Inhibitors

SGLT2 Inhibitors

11-Beta-HSD Type 1 Inhibitors

Beta-3 Adrenergic Agonists

Drugs Targeting Obesity

Noradrenergic Anorectic Agents

Serotonin-Norepinephrine Reuptake Inhibitors

Lipase Inhibitors

Melanin-Concentrating Hormone Receptor Antagonists

Cannabinoid Antagonists

Neuropeptide Y Agonists

Decision Resources, Inc. i DR Pipeline Reports Drugs Targeting Dyslipidemia

Statins (HMG-CoA Reductase Inhibitors)

Fibric Acids

Bile Acid Sequestrants

Nicotinic Acid

Cholesterol Absorption Inhibitors

Cholesteryl Ester Transferase Protein Inhibitors

Squalene Synthase Inhibitors

Microsomal Triglyceride Transfer Protein Inhibitors

Acyl-CoA:Cholesterol Acyltransferase Inhibitors

Chapter 4. Company Profiles

Abbott Laboratories

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Alizyme

Drugs in Development

Amgen

Drugs in Development

Amylin Pharmaceuticals

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

AstraZeneca

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Bristol-Myers Squibb

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Eli Lilly

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

GlaxoSmithKline

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Isis Pharmaceuticals

Drugs in Development

Ligand Pharmaceuticals

Drugs in Development

Merck & Co.

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Metabolex

Drugs in Development

Novartis

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Novo Nordisk

Currently Marketed Drugs for Metabolic Disorders

Decision Resources, Inc. ii DR Pipeline Reports Pfizer

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Roche

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Sanofi-Aventis

Currently Marketed Drugs for Metabolic Disorders

Drugs in Development

Schering-Plough

Currently Marketed Drugs for Metabolic Disorders

Chapter 5. Outlook for Metabolic Disease Therapeutics

Bibliography

Decision Resources, Inc. iii DR Pipeline Reports




Tables and Figures

Table 1. Drugs Available in the United States for the Treatment of Obesity

Table 2. NCEP’s ATP III Classification of LDL, Total, and HDL Cholesterol

Table 3. Drugs Available in the United States for the Treatment of Dyslipidemia

Table 4. Definitions of Metabolic Syndrome

Table 5. Drugs Available in the United States for the Treatment of Type 2 Diabetes (Excluding Insulin)

Table 6. Drugs Available in the United States for the Treatment of Dyslipidemia

Table 7. Abbott Laboratories’ Marketed and Investigational Drugs for Metabolic Diseases

Table 8. Amgen’s Marketed and Investigational Drugs for Metabolic Diseases

Table 9. Select Amgen Alliances in the Metabolic Disease Area, 2000-2005

Table 10. Amylin Pharmaceuticals’ Marketed and Investigational Drugs for Metabolic Diseases

Table 11. Select Amylin Pharmaceuticals Alliances in the Metabolic Disease Area, 2000-2005

Table 12. AstraZeneca’s Marketed and Investigational Drugs for Metabolic Diseases

Table 13. Select AstraZeneca Alliances in the Metabolic Disease Area, 2000-2005

Table 14. Bristol-Myers Squibb’s Marketed and Investigational Drugs for Metabolic Diseases

Table 15. Select Bristol-Myers Squibb Alliances in the Metabolic Disease Area, 2000-2005

Table 16. Eli Lilly’s Marketed and Investigational Drugs for Metabolic Diseases

Table 17. Select Eli Lilly Alliances in the Metabolic Disease Area, 2000-2005

Table 18. GlaxoSmithKline’s Marketed and Investigational Drugs for Metabolic Diseases

Table 19. Select GlaxoSmithKline Alliances in the Metabolic Disease Area, 2000-2005

Table 20. Isis Pharmaceuticals’ Marketed and Investigational Drugs for Metabolic Diseases

Table 21. Select Isis Pharmaceuticals Alliances in the Metabolic Disease Area, 2000-2005

Table 22. Ligand Pharmaceuticals’ Marketed and Investigational Drugs for Metabolic Diseases

Table 23. Select Ligand Pharmaceuticals Alliances in the Metabolic Disease Area, 2000-2005

Decision Resources, Inc. iv DR Pipeline Reports

Table 24. Merck’s Marketed and Investigational Drugs for Metabolic Diseases

Table 25. Select Merck Alliances in the Metabolic Disease Area, 2000-2005

Table 26. Metabolex’s Marketed and Investigational Drugs for Metabolic Diseases

Table 27. Select Metabolex Alliances in the Metabolic Disease Area, 2000-2005

Table 28. Novartis’s Marketed and Investigational Drugs for Metabolic Diseases

Table 29. Select Novartis Alliances in the Metabolic Disease Area, 2000-2005

Table 30. Novo Nordisk’s Marketed and Investigational Drugs for Metabolic Diseases

Table 31. Select Novo Nordisk Alliances in the Metabolic Disease Area, 2000-2005

Table 32. Pfizer’s Marketed and Investigational Drugs for Metabolic Diseases

Table 33. Select Pfizer Alliances in the Metabolic Disease Area, 2000-2005

Table 34. Roche’s Marketed and Investigational Drugs for Metabolic Diseases

Table 35. Select Roche Alliances in the Metabolic Disease Area, 2000-2005

Table 36. Sanofi-Aventis’s Marketed and Investigational Drugs for Metabolic Diseases

Table 37. Select Sanofi-Aventis Alliances in the Metabolic Disease Area, 2000-2005

Table 38. Schering-Plough’s Marketed and Investigational Drugs for Metabolic Diseases




Figure 1. Clinical Progression of Type 2 Diabetes

Figure 2. Insulin-Dependent Glucose Transporter Activation and Expression in Skeletal Muscle or Adipocytes

Figure 3. Mechanisms of Action of the Major Pharmacotherapies for Type 2 Diabetes

Figure 4. Worldwide Insulin Sales, 2004

Figure 5. Metabolic Pipelines: Beyond Phase I

Abstract

Metabolic diseases affect millions of people worldwide. Thousands of metabolic diseases have been identified in humans, yet just a handful of these diseases account for the vast majority of the morbidity and mortality. The World Health Organization (WHO) estimates that type 2 diabetes affects 135 million people worldwide and that 300 million people meet the criteria for obesity. Dyslipidemia is another major metabolic disorder, affecting approximately 300 million people in the United States, Japan, and Western Europe.

Because these three disorders--type 2 diabetes, obesity, and dyslipidemia--are highly prevalent and lead to significant morbidity and mortality, they are the main focus of this report. We also discuss several metabolic disorders that are less severe but account for significant morbidity. These disorders include ""metabolic syndrome"" (which comprises several conditions), polycystic ovarian syndrome (PCOS), and non-alcoholic steatohepatitis (NASH). (We do not discuss hypertension, a common feature of metabolic syndrome, in this report because it is multifactorial in origin and not generally considered a metabolic disorder.)

In this report, we review the etiology and biological features of the aforementioned disorders and discuss the major marketed and emerging classes of drugs used in treatment. (At present, no drugs are commercially available for the treatment of NASH or PCOS.) Following this discussion, we profile companies that either have launched drugs for major metabolic diseases or have drugs in late-stage clinical development. (We do not profile manufacturers of generic drugs targeting these diseases, although we discuss their drugs when relevant.) We conclude with a discussion of the commercial outlook for pharmacological therapies targeting metabolic disorders.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009